{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T03:00:21Z","timestamp":1773802821537,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Key Natural Science Research Projects of Universities in Anhui Province","award":["2024AH050805"],"award-info":[{"award-number":["2024AH050805"]}]},{"name":"Scientific Research Foundation of Anhui Medical University","award":["2023xkj037"],"award-info":[{"award-number":["2023xkj037"]}]},{"name":"National Natural Science Foundation Incubation Program of The Second Affiliated Hospital of Anhui Medical University","award":["2024GQFY03"],"award-info":[{"award-number":["2024GQFY03"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"DOI":"10.1186\/s12935-026-04215-4","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T13:39:18Z","timestamp":1770730758000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["SOX8\/CPT2 axis regulates lipid metabolism to support enzalutamide resistance in prostate cancer"],"prefix":"10.1186","volume":"26","author":[{"given":"Songsong","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dingyong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiyong","family":"Xin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianchao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"issue":"11","key":"4215_CR1","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1007\/s11912-024-01614-6","volume":"26","author":"MNE Almeeri","year":"2024","unstructured":"Almeeri MNE, Awies M, Constantinou C. Prostate Cancer, pathophysiology and recent developments in management: A narrative review. Curr Oncol Rep. 2024;26(11):1511\u20139.","journal-title":"Curr Oncol Rep"},{"issue":"4","key":"4215_CR2","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.eururo.2025.01.010","volume":"87","author":"AA Azad","year":"2025","unstructured":"Azad AA, Kostos L, Agarwal N, Attard G, Davis ID, Dorff T, et al. Combination therapies in locally advanced and metastatic Hormone-sensitive prostate cancer. Eur Urol. 2025;87(4):455\u201367.","journal-title":"Eur Urol"},{"issue":"1","key":"4215_CR3","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.euf.2024.07.012","volume":"11","author":"P Rajwa","year":"2025","unstructured":"Rajwa P, Zapala P, Merseburger AS. Targeting androgen receptor alterations in metastatic prostate cancer. Eur Urol Focus. 2025;11(1):79\u201381.","journal-title":"Eur Urol Focus"},{"key":"4215_CR4","doi-asserted-by":"publisher","first-page":"101359","DOI":"10.1016\/j.mam.2025.101359","volume":"103","author":"D Senapati","year":"2025","unstructured":"Senapati D, Sahoo SK, Nayak BS, Senapati S, Kundu GC, Bhattamisra SK. Targeting and engineering biomarkers for prostate cancer therapy. Mol Aspects Med. 2025;103:101359.","journal-title":"Mol Aspects Med"},{"issue":"26","key":"4215_CR5","doi-asserted-by":"publisher","first-page":"4267","DOI":"10.1200\/JCO.23.00433","volume":"41","author":"C Dai","year":"2023","unstructured":"Dai C, Dehm SM, Sharifi N. Targeting the androgen signaling axis in prostate cancer. J Clin Oncol. 2023;41(26):4267\u201378.","journal-title":"J Clin Oncol"},{"issue":"19","key":"4215_CR6","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1158\/0008-5472.CAN-23-0285","volume":"83","author":"R Sun","year":"2023","unstructured":"Sun R, Yan B, Li H, Ding D, Wang L, Pang J, et al. Androgen receptor variants confer castration resistance in prostate cancer by counteracting Antiandrogen-Induced ferroptosis. Cancer Res. 2023;83(19):3192\u2013204.","journal-title":"Cancer Res"},{"key":"4215_CR7","doi-asserted-by":"publisher","first-page":"217070","DOI":"10.1016\/j.canlet.2024.217070","volume":"597","author":"HJ Chen","year":"2024","unstructured":"Chen HJ, Yu MM, Huang JC, Lan FY, Liao HH, Xu ZH, et al. SLC4A4 is a novel driver of enzalutamide resistance in prostate cancer. Cancer Lett. 2024;597:217070.","journal-title":"Cancer Lett"},{"issue":"11","key":"4215_CR8","doi-asserted-by":"publisher","first-page":"103736","DOI":"10.1016\/j.esmoop.2024.103736","volume":"9","author":"H Bolek","year":"2024","unstructured":"Bolek H, Yazgan SC, Yekeduz E, Kaymakcalan MD, McKay RR, Gillessen S, et al. Androgen receptor pathway inhibitors and drug-drug interactions in prostate cancer. ESMO Open. 2024;9(11):103736.","journal-title":"ESMO Open"},{"key":"4215_CR9","doi-asserted-by":"publisher","first-page":"101047","DOI":"10.1016\/j.neo.2024.101047","volume":"57","author":"J Hu","year":"2024","unstructured":"Hu J, Zhang J, Han B, Qu Y, Zhang Q, Yu Z, et al. PLXNA1 confers enzalutamide resistance in prostate cancer via AKT signaling pathway. Neoplasia. 2024;57:101047.","journal-title":"Neoplasia"},{"issue":"6","key":"4215_CR10","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.7150\/thno.82920","volume":"13","author":"K Yang","year":"2023","unstructured":"Yang K, Wang X, Song C, He Z, Wang R, Xu Y, et al. The role of lipid metabolic reprogramming in tumor microenvironment. Theranostics. 2023;13(6):1774\u2013808.","journal-title":"Theranostics"},{"issue":"7","key":"4215_CR11","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.tem.2024.08.009","volume":"36","author":"X Wang","year":"2025","unstructured":"Wang X, Zhang S, Xue D, Neculai D, Zhang J. Metabolic reprogramming of macrophages in cancer therapy. Trends Endocrinol Metab. 2025;36(7):660\u201376.","journal-title":"Trends Endocrinol Metab"},{"issue":"1","key":"4215_CR12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41420-025-02354-7","volume":"11","author":"G Wei","year":"2025","unstructured":"Wei G, Huang Y, Li W, Xie Y, Zhang D, Niu Y, et al. SREBF1-based metabolic reprogramming in prostate cancer promotes tumor ferroptosis resistance. Cell Death Discov. 2025;11(1):75.","journal-title":"Cell Death Discov"},{"key":"4215_CR13","doi-asserted-by":"crossref","unstructured":"Zekovic M, Bumbasirevic U, Zivkovic M, Pejcic T. Alteration of lipid metabolism in prostate cancer: multifaceted oncologic implications. Int J Mol Sci. 2023;24(2):1391.","DOI":"10.3390\/ijms24021391"},{"issue":"1","key":"4215_CR14","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12967-023-04822-z","volume":"22","author":"Z Wang","year":"2024","unstructured":"Wang Z, Chao Z, Wang Q, Zou F, Song T, Xu L, et al. EXO1\/P53\/SREBP1 axis-regulated lipid metabolism promotes prostate cancer progression. J Transl Med. 2024;22(1):104.","journal-title":"J Transl Med"},{"key":"4215_CR15","doi-asserted-by":"crossref","unstructured":"Gonzalez Alvarado MN, Aprato J. Sox8: a multifaceted transcription factor in development and disease. Biol Open. 2025;14(2):bio061840.","DOI":"10.1242\/bio.061840"},{"issue":"12","key":"4215_CR16","doi-asserted-by":"publisher","first-page":"e22586","DOI":"10.1016\/j.heliyon.2023.e22586","volume":"9","author":"C Li","year":"2023","unstructured":"Li C, Cheng B, Yang X, Tong G, Wang F, Li M, et al. SOX8 promotes tumor growth and metastasis through FZD6-dependent Wnt\/beta-catenin signaling in colorectal carcinoma. Heliyon. 2023;9(12):e22586.","journal-title":"Heliyon"},{"issue":"14","key":"4215_CR17","doi-asserted-by":"publisher","first-page":"e2412985","DOI":"10.1002\/advs.202412985","volume":"12","author":"X Wan","year":"2025","unstructured":"Wan X, Gong R, Zhao X, Li Y, Shan T, Zhong C, et al. Identification of a novel substrate for eEF2K and the AURKA-SOX8 as the related pathway in TNBC. Adv Sci (Weinh). 2025;12(14):e2412985.","journal-title":"Adv Sci (Weinh)"},{"issue":"15","key":"4215_CR18","doi-asserted-by":"publisher","first-page":"6928","DOI":"10.7150\/thno.43811","volume":"10","author":"H Sun","year":"2020","unstructured":"Sun H, Wang H, Wang X, Aoki Y, Wang X, Yang Y, et al. Aurora-A\/SOX8\/FOXK1 signaling axis promotes chemoresistance via suppression of cell senescence and induction of glucose metabolism in ovarian cancer organoids and cells. Theranostics. 2020;10(15):6928\u201345.","journal-title":"Theranostics"},{"issue":"3","key":"4215_CR19","doi-asserted-by":"publisher","first-page":"911","DOI":"10.7150\/ijbs.64752","volume":"18","author":"S Yuan","year":"2022","unstructured":"Yuan S, Xu J, Zhou B, Zhou Y, Lang M, Cao J, et al. SOX8 affects tumoral SPARC expression by regulating EZH2 to attenuate effectiveness of albumin-bound Paclitaxel in PDAC. Int J Biol Sci. 2022;18(3):911\u201322.","journal-title":"Int J Biol Sci"},{"issue":"6","key":"4215_CR20","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1002\/ijc.31134","volume":"142","author":"SL Xie","year":"2018","unstructured":"Xie SL, Fan S, Zhang SY, Chen WX, Li QX, Pan GK, et al. SOX8 regulates cancer stem-like properties and cisplatin-induced EMT in tongue squamous cell carcinoma by acting on the Wnt\/beta-catenin pathway. Int J Cancer. 2018;142(6):1252\u201365.","journal-title":"Int J Cancer"},{"key":"4215_CR21","doi-asserted-by":"publisher","first-page":"103002","DOI":"10.1016\/j.redox.2023.103002","volume":"69","author":"X Yang","year":"2024","unstructured":"Yang X, Gu C, Cai J, Li F, He X, Luo L, et al. Excessive SOX8 reprograms energy and iron metabolism to prime hepatocellular carcinoma for ferroptosis. Redox Biol. 2024;69:103002.","journal-title":"Redox Biol"},{"key":"4215_CR22","doi-asserted-by":"publisher","first-page":"110838","DOI":"10.1016\/j.cellsig.2023.110838","volume":"110","author":"K Zeng","year":"2023","unstructured":"Zeng K, Li Q, Song G, Chen B, Luo M, Miao J, et al. CPT2-mediated fatty acid oxidation inhibits tumorigenesis and enhances Sorafenib sensitivity via the ROS\/PPARgamma\/NF-kappaB pathway in clear cell renal cell carcinoma. Cell Signal. 2023;110:110838.","journal-title":"Cell Signal"},{"issue":"12","key":"4215_CR23","doi-asserted-by":"publisher","first-page":"115064","DOI":"10.1016\/j.celrep.2024.115064","volume":"43","author":"Y Mao","year":"2024","unstructured":"Mao Y, Xia Z, Xia W, Jiang P. Metabolic reprogramming, sensing, and cancer therapy. Cell Rep. 2024;43(12):115064.","journal-title":"Cell Rep"},{"issue":"2","key":"4215_CR24","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/cas.16040","volume":"115","author":"X Sun","year":"2024","unstructured":"Sun X, Zhang Y, Xin S, Jin L, Cao Q, Wang H, et al. NOTCH3 promotes docetaxel resistance of prostate cancer cells through regulating TUBB3 and MAPK signaling pathway. Cancer Sci. 2024;115(2):412\u201326.","journal-title":"Cancer Sci"},{"issue":"4","key":"4215_CR25","doi-asserted-by":"publisher","first-page":"115470","DOI":"10.1016\/j.celrep.2025.115470","volume":"44","author":"G Fidelito","year":"2025","unstructured":"Fidelito G, Todorovski I, Cluse L, Vervoort SJ, Taylor RA, Watt MJ. Lipid-metabolism-focused CRISPR screens identify enzymes of the mevalonate pathway as essential for prostate cancer growth. Cell Rep. 2025;44(4):115470.","journal-title":"Cell Rep"},{"issue":"6320","key":"4215_CR26","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.aah4307","volume":"355","author":"P Mu","year":"2017","unstructured":"Mu P, Zhang Z, Benelli M, Karthaus WR, Hoover E, Chen CC, et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science. 2017;355(6320):84\u20138.","journal-title":"Science"},{"issue":"7","key":"4215_CR27","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1158\/1078-0432.CCR-19-0098","volume":"26","author":"M Nouri","year":"2020","unstructured":"Nouri M, Massah S, Caradec J, Lubik AA, Li N, Truong S, et al. Transient Sox9 expression facilitates resistance to Androgen-Targeted therapy in prostate cancer. Clin Cancer Res. 2020;26(7):1678\u201389.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4215_CR28","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13062-024-00500-2","volume":"19","author":"N Jing","year":"2024","unstructured":"Jing N, Tao Z, Du X, Wen Z, Gao WQ, Dong B, et al. Targeting SOX4\/PCK2 signaling suppresses neuroendocrine trans-differentiation of castration-resistant prostate cancer. Biol Direct. 2024;19(1):56.","journal-title":"Biol Direct"},{"issue":"14","key":"4215_CR29","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1158\/0008-5472.CAN-23-1489","volume":"84","author":"RK Shrestha","year":"2024","unstructured":"Shrestha RK, Nassar ZD, Hanson AR, Iggo R, Townley SL, Dehairs J, et al. ACSM1 and ACSM3 regulate fatty acid metabolism to support prostate cancer growth and constrain ferroptosis. Cancer Res. 2024;84(14):2313\u201332.","journal-title":"Cancer Res"},{"key":"4215_CR30","doi-asserted-by":"crossref","unstructured":"Stoykova GE, Schlaepfer IR. Lipid metabolism and endocrine resistance in prostate Cancer, and new opportunities for therapy. Int J Mol Sci. 2019;20(11):2626.","DOI":"10.3390\/ijms20112626"},{"issue":"5","key":"4215_CR31","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1158\/1541-7786.MCR-18-1147","volume":"17","author":"KD Tousignant","year":"2019","unstructured":"Tousignant KD, Rockstroh A, Taherian Fard A, Lehman ML, Wang C, McPherson SJ, et al. Lipid uptake is an Androgen-Enhanced lipid supply pathway associated with prostate cancer disease progression and bone metastasis. Mol Cancer Res. 2019;17(5):1166\u201379.","journal-title":"Mol Cancer Res"},{"key":"4215_CR32","doi-asserted-by":"publisher","first-page":"1598400","DOI":"10.3389\/fcell.2025.1598400","volume":"13","author":"J Cen","year":"2025","unstructured":"Cen J, Guo J, Zeng X, Song X, Ge S, Chen M, et al. ELOVL2 mediated stabilization of AR contributes to enzalutamide resistance in prostate cancer. Front Cell Dev Biol. 2025;13:1598400.","journal-title":"Front Cell Dev Biol"},{"issue":"12","key":"4215_CR33","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1002\/pros.24027","volume":"80","author":"M Abudurexiti","year":"2020","unstructured":"Abudurexiti M, Zhu W, Wang Y, Wang J, Xu W, Huang Y, et al. Targeting CPT1B as a potential therapeutic strategy in castration-resistant and enzalutamide-resistant prostate cancer. Prostate. 2020;80(12):950\u201361.","journal-title":"Prostate"},{"key":"4215_CR34","doi-asserted-by":"crossref","unstructured":"Xu H, Li S, Sun Y, Xu L, Hong X, Wang Z et al. ELOVL5-Mediated long chain fatty acid elongation contributes to enzalutamide resistance of prostate cancer. Cancers (Basel). 2021;13(16):3957.","DOI":"10.3390\/cancers13163957"},{"issue":"6","key":"4215_CR35","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.tips.2024.04.007","volume":"45","author":"AR Terry","year":"2024","unstructured":"Terry AR, Hay N. Emerging targets in lipid metabolism for cancer therapy. Trends Pharmacol Sci. 2024;45(6):537\u201351.","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"4215_CR36","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12943-024-02119-3","volume":"23","author":"M Tufail","year":"2024","unstructured":"Tufail M, Jiang CH, Li N. Altered metabolism in cancer: insights into energy pathways and therapeutic targets. Mol Cancer. 2024;23(1):203.","journal-title":"Mol Cancer"},{"key":"4215_CR37","doi-asserted-by":"crossref","unstructured":"Pardo JC, Ruiz de Porras V, Gil J, Font A, Puig-Domingo M, Jorda M. Lipid metabolism and epigenetics crosstalk in prostate cancer. Nutrients. 2022;14(4):851.","DOI":"10.3390\/nu14040851"},{"issue":"2","key":"4215_CR38","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1158\/0008-5472.CAN-23-0184","volume":"84","author":"S Ahn","year":"2024","unstructured":"Ahn S, Park JH, Grimm SL, Piyarathna DWB, Samanta T, Putluri V, et al. Metabolomic rewiring promotes endocrine therapy resistance in breast cancer. Cancer Res. 2024;84(2):291\u2013304.","journal-title":"Cancer Res"},{"issue":"6","key":"4215_CR39","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1158\/0008-5472.CAN-20-3477","volume":"81","author":"A Ghoochani","year":"2021","unstructured":"Ghoochani A, Hsu EC, Aslan M, Rice MA, Nguyen HM, Brooks JD, et al. Ferroptosis inducers are a novel therapeutic approach for advanced prostate cancer. Cancer Res. 2021;81(6):1583\u201394.","journal-title":"Cancer Res"},{"issue":"6","key":"4215_CR40","doi-asserted-by":"publisher","first-page":"e449","DOI":"10.1002\/ctm2.449","volume":"11","author":"L Zhou","year":"2021","unstructured":"Zhou L, Zhang C, Yang X, Liu L, Hu J, Hou Y, et al. Melatonin inhibits lipid accumulation to repress prostate cancer progression by mediating the epigenetic modification of CES1. Clin Transl Med. 2021;11(6):e449.","journal-title":"Clin Transl Med"},{"key":"4215_CR41","doi-asserted-by":"crossref","unstructured":"Gu Y, Xue M, Wang Q, Hong X, Wang X, Zhou F et al. Novel strategy of proxalutamide for the treatment of prostate cancer through coordinated Blockade of lipogenesis and androgen receptor axis. Int J Mol Sci. 2021;22(24):13222.","DOI":"10.3390\/ijms222413222"},{"issue":"12","key":"4215_CR42","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1038\/s41418-023-01223-z","volume":"30","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Chen XN, Zhang H, Wen JK, Gao HT, Shi B, et al. CDK13 promotes lipid deposition and prostate cancer progression by stimulating NSUN5-mediated m5C modification of ACC1 mRNA. Cell Death Differ. 2023;30(12):2462\u201376.","journal-title":"Cell Death Differ"},{"issue":"5","key":"4215_CR43","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/s41556-025-01655-4","volume":"27","author":"D Kim","year":"2025","unstructured":"Kim D, Kesavan R, Ryu K, Dey T, Marckx A, Menezes C, et al. Mitochondrial NADPH fuels mitochondrial fatty acid synthesis and lipoylation to power oxidative metabolism. Nat Cell Biol. 2025;27(5):790\u2013800.","journal-title":"Nat Cell Biol"},{"issue":"2","key":"4215_CR44","doi-asserted-by":"publisher","first-page":"725","DOI":"10.7150\/ijbs.102834","volume":"21","author":"Y Guo","year":"2025","unstructured":"Guo Y, Zhang Z, Wen Z, Kang X, Wang D, Zhang L, et al. Mitochondrial SIRT2-mediated CPT2 deacetylation prevents diabetic cardiomyopathy by impeding cardiac fatty acid oxidation. Int J Biol Sci. 2025;21(2):725\u201344.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"4215_CR45","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s41419-025-07644-7","volume":"16","author":"H Wang","year":"2025","unstructured":"Wang H, Dou W, Liu M, Wang W, Yang Y, Li J, et al. SLC25A42 promotes gastric cancer growth by conferring ferroptosis resistance through enhancing CPT2-mediated fatty acid oxidation. Cell Death Dis. 2025;16(1):309.","journal-title":"Cell Death Dis"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-026-04215-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-026-04215-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-026-04215-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T01:04:00Z","timestamp":1773795840000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12935-026-04215-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4215"],"URL":"https:\/\/doi.org\/10.1186\/s12935-026-04215-4","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]},"assertion":[{"value":"14 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the Second Affiliated Hospital of Anhui Medical University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"130"}}